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An emerging paradigm in tumor metabolism is that catabolism in host cells ‘‘fuels’’ the anabolic growth of
cancer cells via energy transfer. A study in Nature Medicine (Nieman et al., 2011) supports this; they
show that triglyceride catabolism in adipocytes drives ovarian cancer metastasis by providing fatty acids
as mitochondrial fuels.Our understanding of tumor metabolism
is evolving. A new central concept in
cancer metabolism is that tumor cells
function as metabolic parasites to extract
energy from supporting host cells, such
as fibroblasts and adipocytes. It has re-
cently been demonstrated that metabolic
coupling exists in human tumors (Sotgia
et al., 2011). In two-compartment tumor
metabolism, the tumor stroma and adja-
cent host tissues are catabolic and the
cancer cells are anabolic (Figure 1). In
this model, energy is transferred from the
catabolic compartment to the anabolic
compartment via the sharing of nutrients
that promote tumor growth, behaving as
onco-metabolites. Although most studies
on two-compartment tumor metabolism
were first performed on fibroblasts and
breast cancer cells (Martinez-Outschoorn
et al., 2011; Sotgia et al., 2011, 2012;
Whitaker-Menezes et al., 2011), an ele-
gant study in Nature Medicine now
broadens this emerging paradigm to adi-
pocytes and ovarian cancer cells (Nieman
et al., 2011).
The tumor cellular microenvironment
contains supporting host cells, including
fibroblasts, adipocytes, smooth muscle
cells, endothelia, and immune cells, which
functionally promote tumor growth. In
two-compartment tumor metabolism, an-
abolic cancer cells extract energy from
the surrounding host cells by inducing
catabolic processes, such as autophagy,
mitophagy, and aerobic glycolysis. These
processes provide high-energymitochon-
drial fuels (L-lactate, ketones, and gluta-4 Cell Metabolism 15, January 4, 2012 ª2012mine) for cancer cells to burn. In response,
cancer cells amplify or hyperactivate
their capacity for oxidative phosphoryla-
tion (OXPHOS) by increasing their mito-
chondrial mass (Sotgia et al., 2012). For
example, cancer-associated fibroblasts
show a shift toward aerobic glycolysis
and secrete L-lactate via MCT4 trans-
porters. L-lactate is taken up by cancer
cells via MCT1 transporters, leading to
thegeneration ofATP viaOXPHOS (Sotgia
et al., 2012). This process can be phe-
nocopied by incubating cancer cells alone
with high-energy fuels, such as L-lactate.
Tumor cells can also exert metabolic
effects at a distance, which leads to in-
creased fatty acid generation in adipose
tissue and catabolism in muscle (Das
et al., 2011). These key examples show
that energy transfer occurs in human
tumors and that cancer cells can exert
metabolic effects locally, in different tumor
compartments, and at distant sites.
Over 80% of ovarian cancers are
metastatic to the omental fat. It is not
known why ovarian cancer cells pre-
ferentially seed the omentum as com-
pared to other sites. To address this issue,
the study by Nieman et al. (2011) uses
SKOV3ip1 human ovarian cancer cells
intraperitoneally (i.p.) injected into nude
mice or cocultured with adipocytes. They
describe how omental adipocytes are
metabolically reprogrammed to become
highly catabolic, generating free fatty
acids that are transferred to cancer cells.
Cancer cells then reutilize these fatty
acids to generate ATP via mitochondrialElsevier Inc.b-oxidation. Utilization of adipocyte-
derived fatty acids was related to the
production of fatty acid binding protein 4
(FABP4) by adipocytes. Importantly, this
study evaluates tumor metabolism in the
more physiological context of its proper
microenvironment.
Energy production and apoptosis are
important mitochondrial functions that
are biologically linked in normal cells.
For example, the mitochondrial proteins
Bcl-2 and Bcl-xL are antiapoptotic and
favor mitochondrial OXPHOS (Chen and
Pervaiz, 2010; Vander Heiden et al.,
2001). A ‘‘mitochondrial paradox’’ exists
in cancer research, since it is not under-
stood why cancer cells, which are resis-
tant to apoptosis, would use energetically
inefficient low mitochondrial metabolism
(aerobic glycolysis, also known as the
Warburg effect) (Le et al., 2010; Fogal
et al., 2010). Interestingly, Nieman et al.
(2011) demonstrate that ovarian cancer
cells have high mitochondrial metabolic
activity, specifically fatty acid b-oxidation,
when cocultured with adipocytes. This
type of mitochondrial metabolism was
not observed when ovarian cancer cells
were cultured alone, highlighting the im-
portance of catabolite transfer to cancer
cells. As such, high-energy nutrients pro-
vided by host cells may bolster mitochon-
drial metabolism in cancer cells, protect-
ing them against apoptosis. The answer
to the ‘‘mitochondrial paradox’’ may lie
in the metabolic reprogramming of can-
cer cells toward anabolic metabolism in
the presence of catabolic host cells,
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Figure 1. Two-Compartment Tumor Metabolism:
Catabolic Host Cells ‘‘Fuel’’ Anabolic Cancer Cell
Growth and Metastasis via Mitochondrial Metabolism
Catabolic host cells that make up the microenvironment (e.g.,
fibroblasts and adipocytes) generate and transfer high-energy
metabolites (L-lactate, ketones, glutamine, and free fatty
acids) to epithelial cancer cells, energetically promoting tumor
growth and metastasis. Cancer cells increase their mitochon-
drial mass and activity (OXPHOS and b-oxidation) to efficiently
burn these energy-rich mitochondrial fuels. Targeted thera-
pies that metabolically uncouple ‘‘parasitic’’ cancer cells
from catabolic host cells (such as mitochondrial inhibitors
[metformin and arsenic trioxide], as well as powerful anti-
oxidants) will starve tumor cells. Effective therapies would
block energy transfer, ‘‘cutting off the fuel supply’’ to cancer
cells.
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and OXPHOS in tumor cells, driv-
ing chemoresistance and distant
metastasis.
Thus, the authors demonstrate
that it is crucial to include the
supporting microenvironment when
studying cancer cell metabolism
and that simply examining primary
cancer cells alone may not be
adequate. Unfortunately, most tradi-
tional cancer metabolism studies
have been carried out using tumor
cells alone, or using whole tumors,
without modeling the host microen-
vironment. As such, one might gain
incomplete or inaccurate informa-
tion by studying primary cancer cells
or cancer cell lines in the absence of
supporting host cells.
Studies describing the compart-
mentalization of tumor metabolism
and energy transfer may pave the
way toward the development of re-
lated predictive biomarkers and
targeted personalized therapies. It
will be important to investigate
whether metabolically uncouplingcancer cells from catabolic host cells
can be used as a new effective anticancer
strategy. Earlier studies have suggested
that the detection of host-tumor meta-
bolic coupling may be useful for identi-
fying high-risk patients at diagnosis in
human breast cancers. For example,
loss of expression of the caveolin-1 pro-
tein in cancer-associated fibroblasts is
a marker for tumor-stroma metabolic
coupling (Sotgia et al., 2011) and is tightly
correlated with recurrence, metastasis,
and tamoxifen resistance as well as
poor clinical outcome.Metabolic coupling
between host cells and breast cancer
cells also results in the generation of reac-
tive oxygen species and inflammatory
cytokine production, such as IL-6 andIL-8 (Sotgia et al., 2012).Most importantly,
FDA-approved drugs that inhibit mito-
chondrial metabolism (metformin, arsenic
trioxide) or strong antioxidants (catalase)
can uncouple two-compartment tumor
metabolism and induce apoptosis in
cancer cells (Martinez-Outschoorn et al.,
2011; Sotgia et al., 2012) (Figure 1).
In conclusion, the importance of the
host microenvironment and energy trans-
fer in cancer metabolism is highlighted by
Nieman et al. (2011). More studies on two-
compartment tumor metabolism will be
necessary to understand and thera-
peutically exploit the metabolic coupling
between ‘‘parasitic’’ tumor cells and their
hosts. Uncoupling ‘‘parasitic’’ cancer
cells should allow us to starve cancer cellsCell Metabolism 15, Jand effectively treat advanced
and metastatic cancers. New imag-
ing techniques to visualize two-
compartment tumor metabolism in
real time will allow us to measure
the effectiveness of anticancer ther-
apies and facilitate more personal-
ized cancer treatments.
REFERENCES
Chen, Z.X., and Pervaiz, S. (2010). Cell
Death Differ. 17, 408–420.
Das, S.K., Eder, S., Schauer, S., Diwoky, C.,
Temmel, H., Guertl, B., Gorkiewicz, G.,
Tamilarasan, K.P., Kumari, P., Trauner, M.,
et al. (2011). Science 333, 233–238.
Fogal, V., Richardson, A.D., Karmali, P.P.,
Scheffler, I.E., Smith, J.W., and Ruoslahti,
E. (2010). Mol. Cell. Biol. 30, 1303–1318.
Le, A., Cooper, C.R., Gouw, A.M., Dinavahi,
R., Maitra, A., Deck, L.M., Royer, R.E., Van-
der Jagt, D.L., Semenza, G.L., and Dang,
C.V. (2010). Proc. Natl. Acad. Sci. USA
107, 2037–2042.
Martinez-Outschoorn, U.E., Goldberg, A.,
Lin, Z., Ko, Y.H., Flomenberg, N., Wang,
C., Pavlides, S., Pestell, R.G., Howell, A.,
Sotgia, F., and Lisanti, M.P. (2011). Cancer
Biol. Ther. 12, 924–938.
n, K.M., Kenny, H.A., Penicka, C.V.,Niema
Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M.R.,
Romero, I.L., Carey, M.S., Mills, G.B., Hotamisligil,
G.S., et al. (2011). Nat. Med. 17, 1498–1503.
Sotgia, F., Martinez-Outschoorn, U.E., Pavlides,
S., Howell, A., Pestell, R.G., and Lisanti, M.P.
(2011). Breast Cancer Res. 13, 213.
Sotgia, F., Martinez-Outschoorn, U.E., Howell, A.,
Pestell, R.G., Pavlides, S., and Lisanti, M.P.
(2012). Annu. Rev. Pathol. 7, 423–467. Published
online November 7, 2011. 10.1146/annurev-
pathol-011811-120856.
Vander Heiden, M.G., Li, X.X., Gottleib, E., Hill,
R.B., Thompson, C.B., and Colombini, M. (2001).
J. Biol. Chem. 276, 19414–19419.
Whitaker-Menezes, D., Martinez-Outschoorn,
U.E., Flomenberg, N., Birbe, R.C., Witkiewicz,
A.K., Howell, A., Pavlides, S., Tsirigos, A., Ertel,
A., Pestell, R.G., et al. (2011). Cell Cycle 10,
4047–4064.anuary 4, 2012 ª2012 Elsevier Inc. 5
